Clinical Trials on Hormone-resistant Prostate Cancer in United Kingdom

Total 7271 results

Stanford University
National Cancer Institute (NCI)

Terminated

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Amgen

Completed

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Castrate-resistant Prostate Cancer

United Kingdom, Czech Republic
Roswell Park Cancer Institute
Dendreon

Completed

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Sandy Srinivas
Wyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaborators

Terminated

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Stanford University

Terminated

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
MacroGenics

Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint Molecule

United States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Institute of Cancer Research, United Kingdom
Sun Pharmaceutical Industries Limited

Terminated

Abiraterone Acetate in Combination With Tildrakizumab (ACTIon)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
University of Nebraska
National Cancer Institute (NCI)

Terminated

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate

United States
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clarus Therapeutics

Recruiting

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Completed

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom, Moldova, Republic of
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Vadim S Koshkin
Eli Lilly and Company; Prostate Cancer Foundation

Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate Carcinoma

United States
Innocrin Pharmaceutical

Completed

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States, Greece, Switzerland, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Soft Tissue Metastases

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis Pharmaceuticals

Terminated

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Prostate Cancer | Castrate Resistant Prostate Cancer | Chemotherapy Naive Prostate Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | Stage IV Prostate Cancer

Singapore, United States
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN)

Prostate Cancer | Refractory Cancer | Castration Resistant Prostatic Cancer

United States
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
Oncternal Therapeutics, Inc

Recruiting

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

United States, United Kingdom
Donald Trump, MD

Terminated

Oral Calcitriol With Ketoconazole in CRPC

Castration-resistant Prostate Cancer

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust and other collaborators

Recruiting

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment (BARCODE2)

Hormone Refractory Prostate Cancer

United Kingdom
Dendreon

Completed

Sipuleucel-T Manufacturing Demonstration Study

Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of Prostate

Austria, France, Netherlands, United Kingdom
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Daniel Vaena

Completed

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Dana-Farber Cancer Institute
Progenics Pharmaceuticals, Inc.

Not yet recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Carcinoma

United States
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate Cancer

United Kingdom
Io Therapeutics

Completed

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
Charles Ryan
Novartis Pharmaceuticals

Terminated

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

Castrate-resistant Prostate Cancer

United States
Prostate Oncology Specialists, Inc.

Completed

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Prostate Cancer | Castrate Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Prostate Neoplasms | Metastatic Castration Resistant Prostate Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics...

Active, not recruiting

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States, Canada, Puerto Rico
University of Cincinnati

Unknown

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Castration-resistant Prostate Cancer | Cancer of the Prostate

United States

Clinical Trials on Hormone-resistant Prostate Cancer in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations